期刊文献+

ER、PR、c-erbB-2在126例乳腺癌的表达及意义 被引量:1

The signification of the expression of ER, PR and c-erbB-2 in breast cancer of 126 cases
下载PDF
导出
摘要 目的 探讨c-erbB-2和ER、PR在乳腺癌中的表达与转移及预后的关系。方法 应用免疫组化技术检测126例原发乳腺癌各抗体的表达情况。结果 ER的阳性率为45.2%,PR的阳性率为53.2%,c-erbB-2阳性率为68.3%。ER、PR其阳性表达率随着临床分期的增高和淋巴结转移数目的增多而逐渐降低,呈负相关,有显著性差异(P<0.05),c-erbB-2的阳性表达率随着临床分期的增高和淋巴结转移数目的增多而增高,呈正相关,有显著性差异(P<0.05)。ER、PR阳性表达率与c-erbB-2呈负相关。结论 ER、PR、c-erbB-2可作为判断乳腺癌生物学行为及预后的有效指标。 Objective To explore the relationship of metastases, prognosis and the expression of ER, PR and c--erB--2 in breast cancer. Method Using Immunohistochemical technique, detect the expression of ER, PR and c--erbB--2 in 126 cases of breast cancer. Results ER positive rate is 45. 2%, PR positive rate 53. 2% and c--erbB--2 positive rate 68. 3%. EP, PR expression rate is negatively correlated with cancer clinical stage and the number of lymphonode metastases (P<0. 05). C--erbB- 2 expression rate is reversed (P<0. 05). Conclusion ER, PR and c--erbB--2 maybe a valuable index as breast canacer prognosis and biological behavior.
作者 周冠严 潘峰
机构地区 温州市肿瘤医院
出处 《福建医药杂志》 CAS 2004年第1期24-25,共2页 Fujian Medical Journal
关键词 ER PR C-ERBB-2 乳腺癌 肿瘤转移 预后 淋巴结转移 Breast cancer LR PR c-erbB-2 Gene Immunohistochemistry
  • 相关文献

参考文献3

二级参考文献10

共引文献22

同被引文献33

  • 1石爱平,许宁,范志民,张哲,王广义,王有德.成人乳腺干细胞中乳腺癌相关基因表达的研究[J].中国老年学杂志,2006,26(7):934-935. 被引量:4
  • 2Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand - binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J]. J Clin Oncol, 1999, 17: 1474 - 1481
  • 3All red D,Mohsin S, Fuqua S. Histological and biological evolution of human premalignant breast disease[J]. Endoer - Rel Cancer, 2001,8 : 47 - 61
  • 4Laura Ciarloni, Sonia Mallepell, Cathrin Brisken. Amphiregulin is an essential mediator of estrogen receptor _ function in mammary gland development [J].PNAS, 2007,104 : 5455 - 5460
  • 5Ross JS, Fletcher JA. The HER - 2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy[J]. Stem Cells, 1998,16:413 - 428
  • 6Quenel N,Wafflart J, Bonichon F, et al. The prognostic value of c-erbB- 2 in primary breast carcinomas: a study on 942 cases[J]. Breast Cancer Res Treat, 1995,35 z 283 - 291
  • 7Toikkanen S, Helin H,Isola J, et al. Prognostic significance of Her-2 oncoprotein expression in breast cancerz a 30- year follow- up[J]. J Clin Oncol,1992,10:1044- 1048
  • 8Tang P, Wang X, Schiffhauer L, et al. Expression patterns of ER- alpha, PR, HER - 2/neu, and EGFR in different cell origin subtypes of high grade and non - high grade ductal carcinoma in situ[J]. Ann Clin Lab Sci,2006,36(2) :137- 143
  • 9Romond EH,Perez EA,Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her2/neu-positive breast cancer[J]. N Engl J Med,2005,353 :1673 - 1684
  • 10Piccart - Gebhart M, Procter M, Leyland - Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2/neu - positive breast cancer[J]. N Engl J Med, 2005,353: 1659 - 1672

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部